Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology

American Journal of Hematology

Volumn 85, Issue 2, 2010, Pages 147-155

  Vitolo, Umberto ^a   Barosi, Giovanni ^b   Fanti, Stefano ^c   Gianni, Alessandro M ^d   Martelli, Maurizio ^e   Petrini, Mario ^f   Zinzani, Pier Luigi ^g   Tura, Sante ^g  

^a MOLINETTE HOSPITAL   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; TEMOZOLOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ASTHENIA; B CELL LYMPHOMA; B CELL NON HODGKIN LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLICULAR LYMPHOMA; FOLLOW UP; GRANULOCYTOPENIA; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; INDOLENT NONFOLLICULAR LYMPHOMA; ITALY; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MEDICAL EXPERT; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; HEMATOLOGY; HUMANS; ITALY; LYMPHOMA, NON-HODGKIN; MELPHALAN; PODOPHYLLOTOXIN; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; SOCIETIES, MEDICAL; TIME FACTORS;

EID: 75449105595     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21602     Document Type: Conference Paper

References (87)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
4. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with Rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-714.
5. Vose JM, Link BK, Grossbard ML, et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's Lymphoma. J Clin Oncol 2001;19:389-397.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
7. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
8. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26:58-65.
9. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984;63:1424-1433.
10. Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017-1025.
11. Gokhale AS, Mayadev J, Pohlman B, Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 2005;63:194-201.
12. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-3803.
13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463.
14. Witzig TE, Flinn IF, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-3269.
15. 90Y- radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imag 2007;34:616-622.
16. William PL, Webb C. The Delphi technique: A methodological discussion. J Adv Nurs 1994;19:180-186.
17. Delbecq AL, van de Ven AH, Gustafson DH.Group Techniques for Program Planning: A guide to nominal group and Delphi processes. Glenview,IL:Scott, Foresman and Co; 1975.
18. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002;99:4336-4342.
19. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 2003;44:465-474.
20. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39:181-194.
21. Wiseman GA, Leigh B, Witzig T, et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 2001;28:1198a.
22. Hagenbeek A, Lewington R. Report of a European consensus workshop to develop recommensations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786-792.
23. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263-1270.
24. Cheung MC, Haynes AE, Stevens A, et al. 90Y-ibritumomab tiuxetan in Lymphoma. Leuk Lymphoma 2006;47:967-977.
25. Grillo-Lopez AJ. 90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin Oncol 2005;32(suppl 1):S44-S49.
26. Emmanouilides C, Murray JL, Vo K, et al. Earlier yttrium-90 ibritumomab tiuxetan (Zevalin) treatment in patients with previously-treated B-cell non-Hodgkin's lymphoma: Higher response rates and longer durations of response. Hematol J 2004;5(Suppl. 2):S8.
27. Schilder RJ, Emmanouilides C, Vo K, et al. Yttrium 90 ibritumomab tiuxetan (Zevalin) is safe and effective in older patients with relapsed or refractory NHL. Proc ASCO 2005;23:a6562.
28. Wiseman GA, Witzig TE, Murray JL, et al. Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade, follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL). Blood 2000;96:a3173.
29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
30. Huglo D, Morschhauser F, Prangère T, et al. Response evaluation of Yttrium-90 Ibritumomab-Tiuxetan (Zevalin®) with Fluor-18 FluoroDeoxyGlucose (FDG-PET). EANM 2006 meeting, Athens, pa486.
31. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
32. Barosi G, Carella A, Lazzarino M, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: Practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005;90:1236-1257.
33. Barosi G, Carella A, Lazzarino M, et al. Management of nodal diffuse large B-cell lymphomas: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006;91:96-103.
34. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285-4292.
35. Armitage JO, Carbone PP, Connors JM, et al. Treatment related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.
36. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-4582.
37. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:629-636.
38. 90Y) ibritumomab tiuxetan therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Haematologica 2005;90:a673.
39. Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. [abstract 6577]. J Clin Oncol 2005; 23(suppl):579s.
40. Gregory SA, Kassar M, Funh HC, et al. A prospective study evaluating the safety and efficacy of combination therapy with fludarabine plus mitoxantrone followed by yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) and maintenance rituximab as front line therapy for patients with intermediate or high risk follicular non-Hodgkin's lymphoma. Blood 2007;110:a1360.
41. Jankowitz RC, Foon KA, DeMonaco NA, et al. Phase II study of short course CHOP rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL) [abstract 8005]. J Clin Oncol 2007;25(Suppl):442s.
42. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352-358.
43. Emmanouilides C. Radioimmunotherapy for Waldenstrom's macroglobulinemia semin Oncology 2003;30:258-261.
44. Emmanouilides C, Silverman D, Leigh B, Territo M. Successful treatment of Waldestrom's with Zevalin based therapy: a case report. Blood 2001;98:a469.
45. Witzig TE, Gordon LI, Emmanouilides C, et al. Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) Blood 2001;98:a4746.
46. Esmaeli B, Pro B, Saville MW, McLaughlin P. Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy may be feasible options in patients with low-grade lymphoma of the orbit. Blood 2005;106:a4792.
47. Vanazzi A, Ferrucci PF, Grana C, et al. Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL). Blood 2007;110:a4499.
48. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856-862.
49. Bartlett NL, Witzig TE, Gordon L, et al. 90Y-Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non Hodgkin's lymphoma (NHL) patients. Proc Am Clin Oncol 2002;21:a51.
50. Syed SA, Madhavi G, Kaplan B, et al. 90Y-Ibritumomab Tiuxetan as a single agent for de novo or transformed diffuse large B cell lymphoma. Blood 2007;110:a4505.
51. Tsimberidou AM, Murray JL, O'Brien S, et al. Yttrium 90-Ibritumomab Tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004;100:2195-2200.
52. Shimoni A, Zwas ST, Oksman Y, et al. Yttrium 90-Ibritumomab Tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007;35:534-540.
53. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium 90-ibritumomab tiuxetan and high-dose chemotherapy in patients with non Hodgkin's lymphoma. J Clin Oncol 2008;26:90-95.
54. Hermann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
55. Jurczak W, Giza A, Zimowska-Curylo D, et al. 90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not illegible for intensive therapy protocols. Blood 2007;110:a4497.
56. Smith MR, Zhang L, Gordon LI, et al. Phase II Study of R-CHOP followed by 90Y-Ibritumomab Tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. Blood 2007;110:a389.
57. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium 90-ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007;110:54-58.
58. Botto B, Bellò M, Benevolo G, et al. Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan (Zevalin) for the treatment of relapsed or resistant aggressive diffuse large B-cell lymphoma (DLBCL) heavily pretreated with Rituximab + Chemotherapy: A GIMURELL experience. Blood 2007;110:a4478.
59. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769-773.
60. Hamlin PA, Moskowitz CH, Wegner BC, et al. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium 90-Ibritumomab Tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL. Blood 2005;106:a926.
61. Venugopal P, Gregory SA, Obrien T, et al. Phase II study of 2-weekly CHOP+ Rituximab followed by Yttrium 90-Ibritumomab Tiuxetan (Zevalin) in patients with previously untreated diffuse large B cell lymphoma (DLBCL). Blood 2007;110:a4507
62. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27:1653-1659.
63. Gisselbrecht C, Decaudin D, Mounier N, et al. 90Yttrium Ibritumomab Tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II Study. Blood 2007;110:a22.
64. Ferrucci PF, Vanazzi A, Grana CM, et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol 2007;139:590-599.
65. Devizzi L, Guidetti A, Tarella C, et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26:5175-182.
66. Nademanee A, Raubitschek A, Molina A, et al. Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-Hodgkin's lymphoma. Blood 2007;110:a1891.
67. Shimoni A, Zwas ST, Oksman Y, et al. Ibritumomab Tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 2008;41:355-361.
68. 90Ibritumomab-Tiuxetan. Leuk Lymphoma 2006;47:59-63.
69. Shah J, Wang W, Harrough VD, et al. Retreatment with yttrium-90 ibritumomb tiuxetan in patients with B cell non Hodgkin's lymphoma. Leuk Lymphoma 2007;48:1736-1744.
70. Witzig TE, Wiseman GA, Geyer SM, et al. A phase I trial of two sequential doses of Zevalin radioimmunotherapy for relapsed low grade B cell non-Hodgkin's lymphoma. Blood 2003;102:a406.
71. Wiseman G, Geyer S, Porrata L. Ongoing results of a phase I trial of two sequential doses of Y-90 Ibritumomab Tiuxetan of patients with relapsed low grade non Hodgkin's lymphoma. Ann Oncol 2005;16(Suppl 5):a333.
72. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non Hodgkin's lymphoma. J Clin Oncol 2002;20:3885-3890.
73. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma 2004;3:202-204.
74. Gordon L, Witzig T, Schilder R, et al. High dose therapy can be safely and successfully administered after Zevalin treatment. Proc Am Soc Clin Oncol 2001;20:232b.
75. Justice T, Martenson J, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer 2006;107:433-438.
76. Ely P, Stearns D, Zaki B, et al. Successful PBPC mobilization, collection, trasnsplatation and engraftment after radioimmunotherapy with Yttrium-90 Ibritumomb Tiuxetan for non Hodgkin's lymphoma. Blood 2005;106:a5517.
77. Zojer N, Mirzaei S, Köhn H, et al. Treatment of a patient with lymphocytepredominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. DGHO Leipzig, 4-8 Nov, 2006.
78. Jaeger G, Linkesch W, Temmel W, Neumeister P. AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient. Lancet Oncol 2005;6:629-631.
79. Pitini V, Baldari S, Altavilla G, et al. Salvage therapy for primary central nervous system lymphoma with 90Y-Ibritumomab and Temozolomide. J Neurooncol 2007;83:291-293.
80. Doolittle ND, Jahnke K, Belanger R, et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 2007;48:1712-1720.
81. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an over-all survival advantage. Blood 2008;111:4004-4013.
82. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-862.
83. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-3457.
84. Murray J, Witzig T, Wiseman G, et al. Zevalin therapy can convert peripheral blood BCL-2 status from positive to negative in patients with low-grade, follicular or transformed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2000;19:a77.
85. Orciuolo E, Buda G, Galimberti S, et al. Role of yttrium-90 ibritumomab tiuxetan (Zevalin®) in inducing and maintaining complete molecular response in B non Hodgkin's lymphoma patients in clinical complete remission after chemotherapy regimen. Blood 2007;110:a4498.
86. 90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory classical hodgkin lymphoma (HL): Delivering cross fire radiation by targeting reactive B cells in the microenvironment. Blood 2005;106:a4791.
87. Zinzani PL, d'Amore F, Bombardieri E, et al. Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice-Report of a European workshop. Eur J Cancer 2008;44:366-373.